Log In
Print
BCIQ
Print
Print this Print this
 

XEN-D0103

  Manage Alerts
Collapse Summary General Information
Company Xention Ltd.
DescriptionPotasssium channel Kv1.5 antagonist
Molecular Target Potassium channel
Mechanism of ActionK channel blocker
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationFibrillation
Indication DetailsTreat and prevent atrial fibrillation (AF)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today